Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (12377)	12/2/1999 11:51:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Thanks, Cacaito. One thing bothers me. You seem to imply that the failure of Biogen with Antova will drive Biogen to success. But if past failures mean future success than XOMA should win hands down, according to many of your past post. If you surrender to this line of reasoning, put your hands up.

To: Cacaito who wrote (12377)	12/3/1999 12:21:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Cacaito, first of all I'd like to have SOME T cells left thank you very much after being treated for Psoriasis. Now apparently either you are wrong or I missed Xoma taking Rituxan through trials before giving it away. Once again you are wrong in being a historian of Xoma and more than bitter about Xoma's new position not only in anti Psoriasis field BUT will also mean POSSIBLE entry with same drug into most inflammatory maladies. NEXT you will be telling me that Pharmas are ALWAYS looking for ways of throwing away 73 million dollars like YOUR scenario with IPIC.LOL